Cardiovascular Effects of Indoramin in Man--a Dose Ranging Study

Overview

Journal Br J Clin Pharmacol

Specialty Pharmacology

Date 1983 Jan 1

PMID 6849741

Citations 6

Authors

D P Nicholls

D W Harron

R G Shanks

Affiliations

Soon will be listed here.

Citing Articles

Effect of indoramin, labetalol and alinidine on sympathetic function in normal man.

Nicholls D, McNeill J, OConnor P, Harron D, Leahey W, Shanks R Br J Clin Pharmacol. 1984; 18(2):215-21.

PMID: 6386022 PMC: 1463526. DOI: 10.1111/j.1365-2125.1984.tb02455.x.

Differential blockade of alpha-adrenoceptors by indoramin.

Nicholls D, OConnor P, Harron D, Leahey W, Shanks R Br J Clin Pharmacol. 1984; 17(6):719-28.

PMID: 6146328 PMC: 1463427. DOI: 10.1111/j.1365-2125.1984.tb02409.x.

Investigation into the cardioregulatory properties of the alpha 1-adrenoceptor blocker indoramin.

Pierce V, Shepperson N, Todd M, Waterfall J Br J Pharmacol. 1986; 87(2):433-41.

PMID: 3955309 PMC: 1916533. DOI: 10.1111/j.1476-5381.1986.tb10834.x.

Indoramin-prolongation of repolarization time, a mechanism of bradycardia in man?.

Harron D, Nicholls D, Shanks R Br J Clin Pharmacol. 1985; 19(2):266-71.

PMID: 3885983 PMC: 1463722. DOI: 10.1111/j.1365-2125.1985.tb02642.x.

Indoramin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in hypertension and related vascular, cardiovascular and airway diseases.

Holmes B, Sorkin E Drugs. 1986; 31(6):467-99.

PMID: 3525084 DOI: 10.2165/00003495-198631060-00002.

References

WENZEL D, Su J . Interactions between sympathomimetic amines and blocking agents on the rat ventricle strip. Arch Int Pharmacodyn Ther. 1966; 160(2):379-89. View

Taylor S, Sutherland G, Mackenzie G, STAUNTON H, Donald K . THE CIRCULATORY EFFECTS OF INTRAVENOUS PHENTOLAMINE IN MAN. Circulation. 1965; 31:741-54. DOI: 10.1161/01.cir.31.5.741. View

GOVIER W . Myocardial alpha adrenergic receptors and their role in the production of a positive inotropic effect by sympathomimetic agents. J Pharmacol Exp Ther. 1968; 159(1):82-90. View

James T, BEAR E, Lang K, Green E . Evidence for adrenergic alpha receptor depressant activity in the heart. Am J Physiol. 1968; 215(6):1366-75. DOI: 10.1152/ajplegacy.1968.215.6.1366. View

Wright B, DORE C . A random-zero sphygmomanometer. Lancet. 1970; 1(7642):337-8. DOI: 10.1016/s0140-6736(70)90709-9. View

Garvey H . Adrenergic mechanisms in the initiation of cardiac arrhythmias. Arch Int Pharmacodyn Ther. 1969; 182(2):376-90. View

Alps B, Hill M, Fidler K, Johnson E, Wilson A . The reversal of experimental cardiac arrhythmias by indoramin (Wy 21901). J Pharm Pharmacol. 1971; 23(9):678-86. DOI: 10.1111/j.2042-7158.1971.tb08744.x. View

Coltart D, Meldrum S, Royds R . Myocardial effects of indoramin hydrochloride, a new hypotensive agent. Br J Pharmacol. 1971; 42(4):664P-665P. PMC: 1665764. View

Alps B, Hill M, Johnson E, Wilson A . Quantitative analysis on isolated organs of the autonomic blocking properties of indoramin hydrochloride (Wy 21901). Br J Pharmacol. 1972; 44(1):52-62. PMC: 1665700. DOI: 10.1111/j.1476-5381.1972.tb07237.x. View

10.

Royds R, Coltart D, Lockhart J . Pharmacologic studies of indoramin in man. Clin Pharmacol Ther. 1972; 13(3):380-92. DOI: 10.1002/cpt1972133380. View

11.

Alps B, BORROWS E, Johnson E, Staniforth M, Wilson A . A comparison of the cardiovascular actions of indoramin, propranolol, lignocaine, and quinidine. Cardiovasc Res. 1972; 6(3):226-34. DOI: 10.1093/cvr/6.3.226. View

12.

Baum T, Shropshire A, ECKFELD D, Metz N, Dinish J, Peters J . Studies relating to the antihypertensive and antidysrhythmic action of indoramin. Arch Int Pharmacodyn Ther. 1973; 204(2):390-406. View

13.

Boakes A, Prichard B, Teoh P . Proceedings: Alpha-adrenoceptor inhibition from indoramin in man. Br J Pharmacol. 1972; 44(2):378P-379P. PMC: 1666013. View

14.

Kramer R, Rosendorff C, Bloom D . Clinical evaluation of indoramin as the sole agent for the treatment of hypertension. S Afr Med J. 1974; 48(37):1569-72. View

15.

Carballo R, Conde L, Lapelle M, Suarez J . The treatment of arterial hypertension with a new alpha-blocker, indoramin. Curr Med Res Opin. 1974; 2(8):437-43. DOI: 10.1185/03007997409115239. View

16.

Baum T, Shropshire A . Central and peripheral contribution to the antihypertensive action of indoramin. Eur J Pharmacol. 1975; 32(1):30-8. DOI: 10.1016/0014-2999(75)90319-2. View

17.

Koch-Weser J . Drug therapy. Hydralazine. N Engl J Med. 1976; 295(6):320-3. DOI: 10.1056/NEJM197608052950606. View

18.

Cambridge D, Davey M, Massingham R . Prazosin, a selective antagonist of post-synaptic alpha-adrenoceptors [proceedings]. Br J Pharmacol. 1977; 59(3):514P-515P. PMC: 1667965. View

19.

Cosnier D, Rispat G, STREICHENBERGER G . Cardiovascular pharmacology of bepridil (1[3 isobutoxy 2 (benzylphenyl) amino] propyl pyrrolidine hydrochloride) a new potential anti-anginal compound. Arch Int Pharmacodyn Ther. 1977; 225(1):133-51. View

20.

Yamaguchi N, de Champlain J, NADEAU R . Regulation of norepinephrine release from cardiac sympathetic fibers in the dog by presynaptic alpha- and beta-receptors. Circ Res. 1977; 41(1):108-117. DOI: 10.1161/01.res.41.1.108. View